Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 743

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 743
---
, 
 September 30,2024  
 ​                  | ​ |       ​ | ​ | ​ 
 ​ | ​ 
 ​ | September 30,2023 
 ​                 | ​ |       ​ | ​ | ​ 
 ​ 
 ​ |
|:---------------------------------------------------------------------------------------------------------------------------|:--|:--|:-------------------|:--|--------:|:--|:--|:--|:------------------|:--|--------:|:--|:--|
| Net loss                                                                                                                   | ​ | ​ | ​                  | $ | -63,188 | ​ | ​ | ​ | ​                 | $ | -86,176 | ​ | ​ |
| Adjustments to reconcile net loss to net cash used in operating activities:                                                | ​ | ​ | ​                  | ​ |       ​ | ​ | ​ | ​ | ​                 | ​ |       ​ | ​ | ​ |
| Stock-based compensation expense                                                                                           | ​ | ​ | ​                  | ​ |   6,575 | ​ | ​ | ​ | ​                 | ​ |  10,129 | ​ | ​ |
| Non-cash interest expense on liability related to sales of future royalties andmilestones, net of issuance costs accretion | ​ | ​ | ​                  | ​ |   5,852 | ​ | ​ | ​ | ​                 | ​ |       — | ​ | ​ |
| Impairment of long-lived assets                                                                                            | ​ | ​ | ​                  | ​ |   4,274 | ​ | ​ | ​ | ​                 | ​ |       ​ | ​ | ​ |
| Inventory write-down                                                                                                       | ​ | ​ | ​                  | ​ |   2,509 | ​ | ​ | ​ | ​                 | ​ |       — | ​ | ​ |
| Depreciation and amortization                                                                                              | ​ | ​ | ​                  | ​ |     192 | ​ | ​ | ​ | ​                 | ​ |     177 | ​ | ​ |
| Noncash lease expense                                                                                                      | ​ | ​ | ​                  | ​ |     766 | ​ | ​ | ​ | ​                 | ​ |   1,221 | ​ | ​ |
| Accretion of available-for-sale marketable securities, net                                                                 | ​ | ​ | ​                  | ​ |    -543 | ​ | ​ | ​ | ​                 | ​ |    -159 | ​ | ​ |
| Changes in operating assets and liabilities:                                                                               | ​